Argenx's Ambitious Plans For Efgartigimod On Track
Second Compound, ARGX-117, Shows Potential
The company's first-in-class FcRn antagonist, which has an FDA action date in December, is now being reviewed by the EMA and although the regulator rejected a request for an accelerated assessment of efgartigimod for generalized myasthenia gravis, commercial teams are being built up in Europe.
